Drugs / Opemalirsen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07154901 | Aug 2025 → Jun 2026 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05351047 | Apr 2022 → Jul 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04269031 | Feb 2020 → Aug 2021 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06824987 | Mar 2025 → Aug 2027 expected | inherited kidney disorder | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Opemalirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07154901 ↗ |
| Known as | AZD2373 | “Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)” NCT07154901 ↗ |
| Route | Subcutaneous | “by SC injection” NCT04269031 ↗ |